2-amino-4-(3-methyl-2-pyrazolidino)-6-chloromethyl-1,3,5-triazine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 三嗪类
• 英文名称: 2-amino-4-(3-methyl-2-pyrazolidino)-6-chloromethyl-1,3,5-triazine
• 英文别名: 4-(chloromethyl)-6-(3-methyl-4,5-dihydro-1H-pyrazol-1-yl)-1,3,5-triazin-2-amine；4-(chloromethyl)-6-(5-methyl-3,4-dihydropyrazol-2-yl)-1,3,5-triazin-2-amine
• 化学式: C₈H₁₁ClN₆
• 分子量: 226.669
• InChiKey: SENXUALRENKBCQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  80.3
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  4-methoxy-3-pyridinesulfonamide 、 2-amino-4-(3-methyl-2-pyrazolidino)-6-chloromethyl-1,3,5-triazine 以 乙腈 为溶剂， 反应 74.0h， 以85%的产率得到1-[2-amino-4-(3-methyl-2-pyrazolino)-1,3,5-triazine-6-yl]methyl-1,4-dihydro-4-oxo-3-pyridinesulfonamide
  参考文献：
  名称：

  Carbonic anhydrase inhibitors. Regioselective synthesis of novel series 1-substituted 1,4-dihydro-4-oxo-3-pyridinesulfonamides and their inhibition of the human cytosolic isozymes I and II and transmembrane cancer-associated isozymes IX and XII

  摘要：

  A series of novel 1-substituted 1,4-dihydro-4-oxo-3-pyridinesulfonamides 4-6, 9-17 and 21-31 have been synthesized and investigated as inhibitors of four isoforms of zinc enzyme carbonic anhydrase (CA.EC 4.2.1.1), that is the cytosolic CA I and II, and cancer-associated isozymes CA IX and XII. Against the human isozymes hCA I the new compounds showed K(I)s in the range of 224-4830 nM, whereas toward hCA II, K(I)s = 318-873 nM. Isozyme hCA IX was inhibited with K(I)s = 11.8-93.4 nM, and hCA XII with 23.5 -82.3 nM. Compounds 12-14, 27 and 29-31 have an activity against hCA I (K(I)s = 224-889 nM) which is comparable to the clinically used sulfonamide DCP (K(I)s = 1200 nM). Several of new compounds, including 9, 10, 21, 24, 26-28 and 30 have an activity against hCA IX (K(I)s = 11.8-38.6 nM) which is comparable or more effective than the clinically used sulfonamides AAZ, MZA, EZA, DCP and IND (K(I)s = 24-50 nM). Compounds 9, 10, 13, 21-23, 26 and 27 were also very effective hCA XII inhibitors, with inhibition constants ranged from 23.5 to 47.2 nM comparable or more effective than sulfonamides EZA (K(I)s = 22 nM) or DCP (K(I)s = 50 nM), respectively. (C) 2012 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2012.08.006
• 作为产物：
  描述：

  氯乙酸甲酯 、 N-(diaminomethylidene)-5-methyl-3,4-dihydropyrazole-2-carboximidamide;hydrochloride 在 sodium methylate 作用下， 以 甲醇 为溶剂， 反应 33.0h， 以74%的产率得到2-amino-4-(3-methyl-2-pyrazolidino)-6-chloromethyl-1,3,5-triazine
  参考文献：
  名称：

  新型2,4-二氨基-1,3,5-三嗪衍生物的合成，结构表征和抗肿瘤活性。

  摘要：

  描述了合成，基于NMR的结构解析和8的X射线分析以及新型2,4-二氨基-1,3,5-三嗪衍生物5和7-22的抗肿瘤活性。在NCI上进行的筛选显示，大多数衍生物在0.148-56.2 microM浓度的各种肿瘤细胞系上具有中等至强的生长抑制活性。2-Amino-6-bromomethyl-4-（3,5,5-trimethyl-2-pyrazoline）-1,3,5-triazine 11显示出最有效的抗肿瘤活性，其平均中点值为log（10）GI50，所有测试的log（10）TGI50和log（10）LC50分别等于-5.26，-4.81和-4.37，因此，可以将其视为抗癌剂进一步开发的先导结构。

  DOI：

  10.1016/s0223-5234(00)01194-6

文献信息

• Carbonic anhydrase inhibitors. Regioselective synthesis of novel series 1-substituted 1,4-dihydro-4-oxo-3-pyridinesulfonamides and their inhibition of the human cytosolic isozymes I and II and transmembrane cancer-associated isozymes IX and XII
  作者：Zdzisław Brzozowski、Jarosław Sławiński、Daniela Vullo、Claudiu T. Supuran

  DOI：10.1016/j.ejmech.2012.08.006

  日期：2012.10

  A series of novel 1-substituted 1,4-dihydro-4-oxo-3-pyridinesulfonamides 4-6, 9-17 and 21-31 have been synthesized and investigated as inhibitors of four isoforms of zinc enzyme carbonic anhydrase (CA.EC 4.2.1.1), that is the cytosolic CA I and II, and cancer-associated isozymes CA IX and XII. Against the human isozymes hCA I the new compounds showed K(I)s in the range of 224-4830 nM, whereas toward hCA II, K(I)s = 318-873 nM. Isozyme hCA IX was inhibited with K(I)s = 11.8-93.4 nM, and hCA XII with 23.5 -82.3 nM. Compounds 12-14, 27 and 29-31 have an activity against hCA I (K(I)s = 224-889 nM) which is comparable to the clinically used sulfonamide DCP (K(I)s = 1200 nM). Several of new compounds, including 9, 10, 21, 24, 26-28 and 30 have an activity against hCA IX (K(I)s = 11.8-38.6 nM) which is comparable or more effective than the clinically used sulfonamides AAZ, MZA, EZA, DCP and IND (K(I)s = 24-50 nM). Compounds 9, 10, 13, 21-23, 26 and 27 were also very effective hCA XII inhibitors, with inhibition constants ranged from 23.5 to 47.2 nM comparable or more effective than sulfonamides EZA (K(I)s = 22 nM) or DCP (K(I)s = 50 nM), respectively. (C) 2012 Elsevier Masson SAS. All rights reserved.
• Synthesis, structural characterization and antitumor activity of novel 2,4-diamino-1,3,5-triazine derivatives
  作者：Z. Brzozowski、F. Sączewski、M. Gdaniec

  DOI：10.1016/s0223-5234(00)01194-6

  日期：2000.12

  The syntheses, structural elucidation based on NMR spectroscopy and X-ray analysis of 8 as well as antitumor activities of novel 2,4-diamino-1,3,5-triazine derivatives 5 and 7-22 are described. Screenings performed at NCI showed that most derivatives possessed a moderate to strong growth inhibition activity on various tumor panel cell lines between 0.148 and 56.2 microM concentrations. 2-Amino-6-bromomethyl-4-(3

  描述了合成，基于NMR的结构解析和8的X射线分析以及新型2,4-二氨基-1,3,5-三嗪衍生物5和7-22的抗肿瘤活性。在NCI上进行的筛选显示，大多数衍生物在0.148-56.2 microM浓度的各种肿瘤细胞系上具有中等至强的生长抑制活性。2-Amino-6-bromomethyl-4-（3,5,5-trimethyl-2-pyrazoline）-1,3,5-triazine 11显示出最有效的抗肿瘤活性，其平均中点值为log（10）GI50，所有测试的log（10）TGI50和log（10）LC50分别等于-5.26，-4.81和-4.37，因此，可以将其视为抗癌剂进一步开发的先导结构。